Findings

What do systematic reviews say?

4,929 questions · 15,174 findings · 2,372 reviews

Sort:Best matchNewestHighest certainty Download CSV

No studies found 15,174 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD

Time to next exacerbation · adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD

Participant satisfaction or preference · adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

Quality of life · adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

Serum deposition Cmax · adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT

Quality of life · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

Time to next exacerbation · adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs nebuliser

Quality of life · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs nebuliser

Serum deposition Cmax · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs nebuliser

Time to next exacerbation · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs ARB

Cardiovascular events · adults with early (stage 1 to 3) non‐diabetic CKD

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs ARB

Adverse events · adults with early (stage 1 to 3) non‐diabetic CKD

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs ARB

Kidney failure progression · adults with early (stage 1 to 3) non‐diabetic CKD

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

Kidney failure progression: doubling of SCr (mg/dL) · adults with early (stage 1 to 3) non‐diabetic CKD

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin receptor blockers (ARBs) vs placebo

Cardiovascular events · adults with early (stage 1 to 3) non‐diabetic CKD

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs ARB

Death (any cause) · adults with early (stage 1 to 3) non‐diabetic CKD

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: ACBT vs CCPT

Quality of life · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: ACBT vs PEP mask therapy

Adverse events · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: ACBT vs PEP mask therapy

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: ACBT vs PEP mask therapy

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: ACBT vs PEP mask therapy

Sputum weight (change from baseline) · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found